Wealth Enhancement Advisory Services
ORMP icon

Wealth Enhancement Advisory Services’s Oramed Pharmaceuticals ORMP Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.1K Sell
12,895
-604
-4% -$2.4K ﹤0.01% 3910
2026
Q1 		$46.2K Sell
13,499
-4,800
-26% -$16.3K ﹤0.01% 3438
2025
Q4 		$56.2K Sell
18,299
-500
-3% -$1.29K ﹤0.01% 3526
2025
Q3 		$46.6K Hold
18,799
– – ﹤0.01% 3439
2025
Q2 		$41K Buy
18,799
+5,000
+36% +$11K ﹤0.01% 3247
2025
Q1 		$29.5K Hold
13,799
– – ﹤0.01% 2891
2024
Q4 		$33.4K Buy
13,799
+2,499
+22% +$5.94K ﹤0.01% 2886
2024
Q3 		$27.6K Sell
11,300
-100
-0.9% -$244 ﹤0.01% 2654
2024
Q2 		$29.3K Hold
11,400
– – ﹤0.01% 2472
2024
Q1 		$33.3K Sell
11,400
-500
-4% -$1.4K ﹤0.01% 2362
2023
Q4 		$27.5K Hold
11,900
– – ﹤0.01% 2241
2023
Q3 		$31.1K Buy
+11,900
New +$37.5K ﹤0.01% 2180

Other funds holding ORMP

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
SCM
Sage Capital Management Stockton, New Jersey $256M AUM 29.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
GJIA
Glass Jacobson Investment Advisors Owings Mills, Maryland $321M AUM 20.69% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $194M AUM
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

Wealth Enhancement Advisory Services's ORMP Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Oramed Pharmaceuticals (ORMP) stake by 4.5% in Q2 2026, selling an estimated $2.4K and leaving 12,895 shares worth $52.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3910.

Wealth Enhancement Advisory Services first reported a position in ORMP in Q3 2023 and has held it in 12 quarters since. The position peaked at $56.2K in Q4 2025. 14 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Wealth Enhancement Advisory Services held 12,895 shares of Oramed Pharmaceuticals worth $52.1K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 604 Oramed Pharmaceuticals shares in Q2 2026, an estimated $2.4K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3910 holding.
  • Wealth Enhancement Advisory Services first reported a position in Oramed Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Wealth Enhancement Advisory Services's Oramed Pharmaceuticals position peaked at $56.2K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.